View Older Stories View More Recent Stories

Jun 19, 2017 07:03AM Standardizing on Veeva Vault Enhances Regeneron’s Clinical and Regulatory Operations Processes
Jun 19, 2017 07:03AM Industry Survey Reveals 99% of Clinical Operations Leaders Report the Need to Unify Their Clinical Applications
Jun 19, 2017 07:03AM Industry Survey Reveals 99% of Clinical Operations Leaders Report the Need to Unify Their Clinical Applications
Jun 12, 2017 05:53AM Sanofi (SNY) & Regeneron (REGN) Presents Positive Results on Praluent (alirocumab) for Patients with Diabetes & Hypercholesterolemia
Jun 11, 2017 11:01AM Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Jun 11, 2017 11:01AM Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Jun 11, 2017 11:00AM Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Jun 5, 2017 06:28AM Regeneron (REGN) & Sanofi (SNY) Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at ASCO Meetings
Jun 4, 2017 10:00AM Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 4, 2017 10:00AM Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
May 24, 2017 05:01PM Regeneron (REGN) Says Data on ANGPTL3/Evinacumab Published in NEJM
May 24, 2017 05:00PM Regeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive Phase 2 Data in People with HoFH
May 22, 2017 05:52PM Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
May 22, 2017 05:47PM Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
May 22, 2017 05:46PM Regeneron (REGN), Sanofi (SNY) Announce FDA Approval of Kevzara for RA
May 22, 2017 05:45PM Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
May 18, 2017 09:30AM Regeneron Announces Upcoming Investor Conference Presentations
May 8, 2017 08:30AM Regeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment in Kidney Cancer
May 8, 2017 07:46AM Regeneron (REGN), Inovio (INO) Enter Agreement for Glioblastoma Combination Therapy
May 8, 2017 07:30AM Inovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
May 8, 2017 07:30AM Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
May 5, 2017 09:30AM Regeneron Announces Upcoming Investor Conference Presentations
May 4, 2017 06:30AM Regeneron Reports First Quarter 2017 Financial and Operating Results
May 2, 2017 08:30AM Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment
May 2, 2017 08:30AM Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment
Apr 28, 2017 05:45AM Sanofi (SNY) & Regeneron (REGN) Report Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by FDA
Apr 28, 2017 01:00AM Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA
Apr 25, 2017 08:05AM Regeneron (REGN), Sanofi (SNY) Announce FDA Approval of sBLA for Once-Monthly Dosing Option for Praluent
Apr 25, 2017 08:03AM Sanofi (SNY) & Regeneron Pharmaceuticals (REGN) Report FDA Approval of a New Once-Monthly Dosing Option for Praluent® (Alirocumab) Injection
Apr 25, 2017 08:00AM Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection
Apr 25, 2017 08:00AM Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection
Apr 24, 2017 05:47AM Regeneron (REGN) & Sanofi (SNY) Announce Positive CHMP Opinion on Kevzara® (sarilumab) from European Medicine Agency
Apr 24, 2017 01:00AM Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Apr 14, 2017 09:30AM Regeneron to Report First Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2017
Apr 6, 2017 11:23AM Regeneron Science Talent Search to Ring The Nasdaq Stock Market Closing Bell
Apr 6, 2017 07:01AM Regeneron (REGN) Reports Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia (HoFH)
Apr 6, 2017 07:00AM Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia (HoFH)
Mar 28, 2017 01:50PM Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval
Mar 28, 2017 11:56AM Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Mar 28, 2017 11:41AM Regeneron (REGN) and Sanofi (SNY) Announce FDA Approval of DUPIXENT to Treat Moderate-to-Severe Atopic Dermatitis
Mar 28, 2017 11:40AM Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Mar 28, 2017 11:40AM Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Mar 23, 2017 05:38AM Regeneron (REGN), U.K. Biobank and GSK to Launch DNA Sequencing Database Initiative from 500K U.K. Volunteers
Mar 22, 2017 08:00PM U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis
Mar 14, 2017 10:45PM Teen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017
Mar 14, 2017 09:29PM Teen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017
Mar 7, 2017 08:05AM Regeneron (REGN), Sanofi (SNY) to Present New Phase 3 Praluent Injection Trial Analyses at ACC
Mar 7, 2017 08:00AM Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions
Mar 4, 2017 10:30AM Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of Dupixent® (dupilumab) in Moderate-to-Severe Atopic Dermatitis
Mar 4, 2017 10:30AM Regeneron and Sanofi Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DUPIXENT® (dupilumab) in Moderate-to-Severe Atopic Dermatitis
View More Recent Stories View Older Stories